Kahalalide F Enters Phase II Trials
Madrid - Spanish PharmaMar S.A. recently announced that Kahalalide F has begun Phase II trials in non-small cell lung cancer (NSCLC) and in melanoma. These trials are based on the strength of Phase I results when this compound showed a very favourable safety profile and clinical benefit in NSCLC and melanoma as well as in a broad spectrum of tumour types. Kahalalide F is a new marine compound derived from the sea slug Elysia rufescens.
According to the WHO, every year there are more than 1.2 million new cases worldwide of lung and bronchial cancer.